Contineum’s J&J-partnered drug fails Phase 2 multiple sclerosis trialnews2025-11-21T15:19:47+00:00November 21st, 2025|Endpoints News|
GSK, AnaptysBio enter legal battle over decade-old Jemperli licensing dealnews2025-11-21T12:07:36+00:00November 21st, 2025|Endpoints News|
Jeff Bluestone, Stephen Dilly talk CEO handoff, what’s next for Sonoma; Scott Gottlieb’s next movenews2025-11-21T12:00:57+00:00November 21st, 2025|Endpoints News|
Under RFK Jr., vaccine use has slid while suspicion risesnews2025-11-20T20:47:17+00:00November 20th, 2025|Endpoints News|
Pentagon-backed Lumen is ready to drastically slash antibody manufacturing costsnews2025-11-20T20:46:37+00:00November 20th, 2025|Endpoints News|
Function Health’s unicorn moment (and lurking competition)news2025-11-20T20:12:09+00:00November 20th, 2025|Endpoints News|
Novartis, Moderna detail manufacturing expansions in the US, among othersnews2025-11-20T17:56:16+00:00November 20th, 2025|Endpoints News|
Abbott’s $21B diagnostic deal; Job cuts at Applied Therapeutics and AbbVienews2025-11-20T16:38:35+00:00November 20th, 2025|Endpoints News|
Dispatches from Jefferies: Why Alkermes wants Avadel, Light Chain’s hope for CD47, and morenews2025-11-20T16:33:02+00:00November 20th, 2025|Endpoints News|
AbbVie, Novartis can proceed with legal fight against Utah 340B lawnews2025-11-20T15:40:44+00:00November 20th, 2025|Endpoints News|
